proassurance corp. - PRA
PRA
Close Chg Chg %
24.45 -0.11 -0.43%
Closed Market
24.35
-0.11 (0.43%)
Volume: 635.37K
Last Updated:
Feb 6, 2026, 3:59 PM EDT
Company Overview: proassurance corp. - PRA
PRA Key Data
| Open $24.48 | Day Range 24.31 - 24.48 |
| 52 Week Range 13.90 - 24.61 | Market Cap $1.26B |
| Shares Outstanding 51.41M | Public Float 50.64M |
| Beta 0.10 | Rev. Per Employee N/A |
| P/E Ratio 37.36 | EPS $0.66 |
| Yield 0.00% | Dividend $0.05 |
| EX-DIVIDEND DATE Mar 28, 2023 | SHORT INTEREST N/A |
| AVERAGE VOLUME 520.06K |
PRA Performance
| 1 Week | 0.54% | ||
| 1 Month | 1.25% | ||
| 3 Months | 1.33% | ||
| 1 Year | 64.19% | ||
| 5 Years | 22.55% |
PRA Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
4
Full Ratings ➔
An error occurred while fetching the data.
An error occurred while fetching the data.
Snapshot
| Average Recommendation | UNDERWEIGHT | Average Target Price | 25.00 | |
| Number of Ratings | 4 | Current Quarters Estimate | 0.21 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 1.137 | |
| Last Quarter’s Earnings | 0.249 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 1.058 | Next Fiscal Year Estimate | 1.095 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 2 | 2 | 4 | 2 |
| Mean Estimate | 0.21 | 0.26 | 1.14 | 1.10 |
| High Estimates | 0.25 | 0.30 | 1.25 | 1.35 |
| Low Estimate | 0.17 | 0.22 | 0.90 | 0.84 |
| Coefficient of Variance | 26.94 | 21.76 | 14.06 | 32.93 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 0 | 0 | 0 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 3 | 3 | 4 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 1 | 1 | 1 |
| MEAN | Underweight | Underweight | Hold |
SEC Filings for Proassurance Corp. - PRA
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Proassurance Corp. - PRA
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 27, 2025 | Jeffrey Patton Lisenby Executive Vice-President | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | Robert David Francis Pres Healthcare Pro. Liability | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | Dana Shannon Hendricks Chief Financial Officer | 37,020 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $16.13 per share | 597,132.60 |
| Feb 27, 2025 | Dana Shannon Hendricks Chief Financial Officer | 33,040 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $16.13 per share | 532,935.20 |
| Feb 27, 2025 | Kevin Merrick Shook President of a Subsidiary | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | Kevin Merrick Shook President of a Subsidiary | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | Kevin Merrick Shook President of a Subsidiary | 17,668 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Kevin Merrick Shook President of a Subsidiary | 39,027 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.13 per share | 629,505.51 |
| Feb 27, 2025 | Kevin Merrick Shook President of a Subsidiary | 44,796 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $16.13 per share | 722,559.48 |
| Feb 27, 2025 | Kevin Merrick Shook President of a Subsidiary | 40,816 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $16.13 per share | 658,362.08 |
| Feb 27, 2025 | Jeffrey Patton Lisenby Executive Vice-President | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | Edward Lewis Rand President & CEO; Director | 241,884 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $16.13 per share | 3,901,588.92 |
| Feb 27, 2025 | Jeffrey Patton Lisenby Executive Vice-President | 17,668 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Jeffrey Patton Lisenby Executive Vice-President | 83,914 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.13 per share | 1,353,532.82 |
| Feb 27, 2025 | Jeffrey Patton Lisenby Executive Vice-President | 89,685 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $16.13 per share | 1,446,619.05 |
| Feb 27, 2025 | Jeffrey Patton Lisenby Executive Vice-President | 85,705 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $16.13 per share | 1,382,421.65 |
| Feb 27, 2025 | Edward Lewis Rand President & CEO; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | Edward Lewis Rand President & CEO; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | Edward Lewis Rand President & CEO; Director | 71,295 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Edward Lewis Rand President & CEO; Director | 235,414 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $16.13 per share | 3,797,227.82 |